RegulatoryCompany release

FDA approves Roche's Gazyva for primary membranous nephropathy, a first for the condition

Roche · Mon 16 Nov 2026

The US regulator has cleared obinutuzumab for adults with primary membranous nephropathy at risk of progression, based on phase III MAJESTY data against tacrolimus.

Roche announced on 16 November 2026 that the US Food and Drug Administration has approved Gazyva (obinutuzumab, marketed as Gazyvaro outside the US) for adults with primary membranous nephropathy who are at risk of disease progression. The indication is to induce remission of proteinuria. Roche describes it as the first therapy approved for this kidney disease.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release: Roche ↗

Article written by VigiEye from the official source (Roche). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →